Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Esperion Therapeutis.Inc. buy StockNews.com

Start price
€1.70
17.08.25 / 50%
Target price
-
17.08.26
Performance (%)
51.90%
Price
€2.56
07:47
Summary
This prediction is currently active. With a performance of 51.90% the BUY prediction by StockNews_com is a big success. This prediction currently runs until 17.08.26. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w 1m
Esperion Therapeutis.Inc. 18.380% 18.380%
iShares Core DAX® 2.850% 3.312%
iShares Nasdaq 100 1.612% 5.652%
iShares Nikkei 225® 6.401% 11.958%
iShares S&P 500 1.346% 4.130%

Comments by StockNews_com for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat

Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.93
26.10.24
-
26.10.25
37.54%
07:47

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.97
05.10.24
-
05.10.25
41.81%
06.10.25